Nephrology Doctors in Tallahassee, FL Accepting Medicare

6 Nephrology doctors found. Showing 1 - 6

Dr. Hari K. Kolli, M.B.B.S. (M.D.) Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2617 Mitcham Dr Ste 102, Tallahassee, FL 32308 Phone: 850-878-1171    Fax: 850-942-1291

Mr. Gary Paul Hansen, MD Internal Medicine - Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1609 Physicians Dr, Tallahassee, FL 32308 Phone: 850-878-1171    Fax: 850-942-1291

Mr. Harold Avon Doll Jr., MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2617 Mitcham Dr Ste 102, Tallahassee, FL 32308 Phone: 850-878-1171    Fax: 850-942-1291

Kaushal P Patel, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2617 Mitcham Dr Ste 102, Tallahassee, FL 32308 Phone: 850-878-1171    Fax: 850-942-1291

Dr. Hiren Jagdish Joshi, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1845 Jaclif Ct, Tallahassee, FL 32308 Phone: 850-999-2328    Fax: 850-320-6114

Mr. Clarence William Applegate, MD Internal Medicine - Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1609 Physicians Dr, Tallahassee, FL 32308 Phone: 850-878-1171    Fax: 850-942-1291

News Archive

Children of deployed parents more likely to suffer mental health problems

The New York Times: "Young children in military families are about 10 percent more likely to see a doctor for a mental difficulty when a parent is deployed than when the parent is home, researchers are reporting Monday in the most comprehensive study to date of such families' use of health insurance during wartime."

Henry Schein authorizes repurchase of $200M shares of common stock

Henry Schein, Inc., the largest provider of health care products and services to office-based practitioners, today announced that its Board of Directors has authorized the repurchase of up to $200 million of shares of the Company's common stock.

KineMed extends collaboration with CHDI Foundation to track pathogenesis of Huntington's disease

KineMed, Inc. and CHDI Foundation, Inc. announced today an extension of their collaboration that uses KineMed's translational biomarker platform to characterize and track the pathogenesis of Huntington's disease (HD) and evaluate potentially therapeutic interventions.

Industrial Biotechnology presents insights on cellulose nanocrystal toxicity

Novel nanomaterials derived from cellulose have many promising industrial applications, are biobased and biodegradable, and can be produced at relatively low cost. Their potential toxicity-whether ingested, inhaled, on contact with the skin, or on exposure to cells within the body-is a topic of intense discussion, and the latest evidence and insights on cellulose nanocrystal toxicity are presented in a Review article in Industrial Biotechnology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Genetic testing could help determine drug dosage, reduce side effects

Usually pharmaceutical companies determine the drug dosage just as a mean value. This amount may be too much for patients who absorb the substance faster, and too little for those with a slower metabolism.

Read more Medical News

› Verified 3 days ago